We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -3.00 | -8.96% | 30.50 | 134,892 | 14:35:45 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 30.00 | 31.00 | 33.50 | 30.50 | 33.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 29.49M | USD -302k | USD -0.0043 | -70.93 | 23.64M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:06:06 | O | 5,000 | 30.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 09/6/2025 | 11:22 | ALNC |  Tissue Regenix receives EU certification for OrthoPure XT technology |
| 09/6/2025 | 07:00 | UK RNS | Tissue Regenix Group PLC CE & UKCA certification for OrthoPure® XT |
| 24/4/2025 | 09:38 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI)- Tissue Regenix Group Plc |
| 15/4/2025 | 09:23 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
| 10/4/2025 | 09:09 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
| 09/4/2025 | 10:45 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
| 08/4/2025 | 07:00 | UK RNS | Tissue Regenix Group PLC Conclusion of Strategic Review & Offer Period |
| 07/4/2025 | 08:46 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
| 01/4/2025 | 09:12 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
| 31/3/2025 | 09:21 | UK RNS | Cavendish Securities PLC Form 8.5 (EPT/NON-RI) |
Tissue Regenix (TRX) Share Charts1 Year Tissue Regenix Chart |
|
1 Month Tissue Regenix Chart |
Intraday Tissue Regenix Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 20/6/2025 | 17:46 | Tissue Regenix delivering practical solutions to real clinical issues | 7,978 |
| 27/9/2021 | 18:42 | Tissue Regenix takes pole position in regeneration game | 2 |
| 26/5/2020 | 13:31 | Torex with Charts & News | 14 |
| 15/1/2020 | 07:09 | TOREX 2007 - THE TILLS RING AT LAST | 13 |
| 14/1/2020 | 20:51 | Terrane Minerals- Cu explorer, trading in Canada | 17 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-06-20 16:06:07 | 30.50 | 5,000 | 1,525.00 | O |
| 2025-06-20 15:27:24 | 30.95 | 5,000 | 1,547.50 | O |
| 2025-06-20 15:09:25 | 30.78 | 1,000 | 307.80 | O |
| 2025-06-20 14:53:02 | 30.68 | 5,000 | 1,534.00 | O |
| 2025-06-20 14:33:29 | 30.15 | 32,263 | 9,727.29 | O |
| Top Posts |
|---|
Posted at 21/6/2025 09:20 by Tissue Regenix Daily Update Tissue Regenix Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 33.50p.Tissue Regenix currently has 70,574,468 shares in issue. The market capitalisation of Tissue Regenix is £21,525,213. Tissue Regenix has a price to earnings ratio (PE ratio) of -70.93. This morning TRX shares opened at 33.50p |
Posted at 20/6/2025 17:46 by cerrito Seems to have been an active trading day by TRX standards today which no doubt explains the late price fall.People spooked by lack of news about annual results so close to 6 month cut off? Or something more specific? Hopefully news on Monday. |
Posted at 09/6/2025 07:32 by p1nkfish TU soon and good to see MDR announced today. Take with a pinch of salt but I do think this is close to the mark."With EU MDR approval, OrthoPure® XT can unlock: A US $125– Supportive global niche (~US $30– A stepping stone into broader knee biologics and multi‑ligament procedures in a US $2–4& These estimates align well with Tissue Regenix’s 2024-2030 strategic pillar to scale dCELL® products across EU and outside EU markets." I suspect no sale of the company went through because of the price tag. TRX wouldn't sell themselves cheap given the potential. Some future time they will be acquired imho for a decent price compared to today - many multiples imho. Dyor etc as this may be totally wrong, just my thoughts. |
Posted at 08/4/2025 11:11 by hedgehog 100 08/04/2025 07:00 RNS Regulatory News Tissue Regenix Group PLC Conclusion of Strategic Review & Offer Period LSE:TRX Tissue Regenix Group Plc"... The Board believes the Company's valuation is now at a level which bears no resemblance to the prospects or the typical valuation that a business in this sector would be ascribed; the Board believes that despite varying degrees of interest in the Company, the current equity value cannot be used as a base from which a strategic transaction can occur. The Board, in conjunction with advisors and major shareholders, will continue to assess the best route forward to deliver the substantial value that exists in this business, which is not being reflected in the share price today. The Board has determined that based on discussions to date, it does not believe there is a prospect of an appropriate offer for the issued, and to be issued, share capital of Tissue Regenix being forthcoming in the near term. Accordingly, the Company is no longer in discussions with any interested parties. ..." The company is in effect saying that its AIM listing is scuppering any chance of a strategic transaction at a decent price, which is what they seem to want, to deliver greater value. The logical conclusion from this therefore would be to delist, like so many other shares are doing at the moment. So I think there's an odds-on possibility that this will happen, in the not too distant future. |
Posted at 08/4/2025 07:36 by bamboo2 ('Tissue Regenix', the 'Group' or the 'Company')Conclusion of Strategic Review & Offer Period Company continues to deliver growth and expects a second year of profitability Tissue Regenix (AIM: TRX), the regenerative medical devices company, provides the following update on its review of strategic options announced late last year. On 4 November 2024, the board of directors of Tissue Regenix (the "Board") announced that it was undertaking a review of the Company's strategic options, that included soliciting offers for the Company, on a focused and targeted basis (the "Strategic Review"). This Strategic Review has enabled the Company to evaluate material possible corporate transactions, including the sale of the whole of the Company. The Board regularly assesses the options set against the value which the stock market ascribes to the Company. With the share price in November standing at 57p, the Board unanimously felt that the value of the Company was not representative of the prospects and delivery which had been seen over the last 3+ years. The Company had delivered eight consecutive reporting periods of growth and demonstrated profitability on an adjusted EBITDA* basis for 2023 and H1 2024. Since the announcement of the Strategic Review, the Company has continued to deliver growth and produced a strong 2024 trading update, as announced on 30 January 2025. Total Group revenue for the year ended 31 December 2024 is expected to increase by 8% to $28.4m (2023: $26.3m), and the Company expects to once again report an adjusted EBITDA profit above expectations. Since the announcement of the Strategic Review in November 2024, the Company has extended its relationship with one of its major customers (Arthrex), announced that adjusted EBITDA would be ahead of expectations and been granted an important European patent. Despite these multiple positive developments, the share price has fallen over 30% reflecting a challenging market environment for small cap companies which is of serious concern for the Board. The Board believes the Company's valuation is now at a level which bears no resemblance to the prospects or the typical valuation that a business in this sector would be ascribed; the Board believes that despite varying degrees of interest in the Company, the current equity value cannot be used as a base from which a strategic transaction can occur. The Board, in conjunction with advisors and major shareholders, will continue to assess the best route forward to deliver the substantial value that exists in this business, which is not being reflected in the share price today. The Board has determined that based on discussions to date, it does not believe there is a prospect of an appropriate offer for the issued, and to be issued, share capital of Tissue Regenix being forthcoming in the near term. Accordingly, the Company is no longer in discussions with any interested parties. Consequently, the Board has decided to terminate the Strategic Review, and the Company is no longer in an offer period as defined by the City Code on Takeovers and Mergers (the "Takeover Code"). As a result, the disclosure requirements pursuant to Rule 8 of the Takeover Code are no longer applicable with effect from the publication of this announcement. Accordingly, the Board will focus on delivering sustainable growth as a standalone independent entity and look forward to further growth in 2025 and beyond. * Adjusted EBITDA: profit before interest, taxes, depreciation, amortisation and share-based payments Daniel Lee, CEO of Tissue Regenix, commented: "As we announced at the time of our Trading Update, the 4S strategy and our growth pillars continued to deliver growth and we have not wavered from executing on the plans which drive the business forward. Demand for our market differentiated tissue products remains strong and will be augmented with product line enhancements with existing and new customers to drive additional growth in 2025. Our flexibility has given us the ability to weather the significant regulatory and market changes we have encountered over the last year. This strategic process has not changed our growth strategy across all of our divisions." |
Posted at 22/3/2025 08:29 by p1nkfish Haven't paid to read it but TRX gets a mention and in this could be a future potential acquirer.Smith & Nephew Plc (U.K.), MiMedx (U.S.), Tissue Regenix (U.K.), Integra LifeSciences Corporation (U.S.), Organogenesis Inc. (U.S.), Zimmer Biomet (U.S.), NOUVAG AG (Switzerland), De Soutter Medical (U.K.), Mallinckrodt (U.K.), B. Braun Melsungen AG (Germany), AVITA Medical (U.K.), Surtex Instruments Limited (U.K.), Exsurco Medical, Inc. (U.S.), Specmed (Poland), ConvaTec Inc. (U.K.), CryoLife, Inc. (U.S.), Athersys Inc. (U.S.), LifeNet Health (U.S.), U.S. Stem Cell, Inc. (U.S.), Isto Biologics (U.S.), Allergan (U.S.) |
Posted at 21/3/2025 10:37 by hedgehog 100 The extreme and sudden share price movement downwards here ahead of news, with no explanation from the company, is different from just a gentle drift downwards in bad markets.It is more like the recent move downwards at Oncimmune (ONC):- 17/03/2025 07:00 RNS Regulatory News Oncimmune Holdings PLC Intention to Appoint Administrators and Suspension LSE:ONC Oncimmune Holdings Plc |
Posted at 20/3/2025 16:40 by hedgehog 100 The difference to Eckoh though, Tnt99, is that ECK was going UP ahead of news, whereas TRX is going DOWN ahead of news ...So the probability is that the strategic review will result in something bad for the TRX s.p.: e.g.-i.e. a discounted fundraising, a delisting without a takeover, or a lowball takeover. |
Posted at 20/3/2025 16:11 by p1nkfish TRX are in a really useful area and I find it hard not to see it worth more than the current market cap to someone. |
Posted at 25/11/2024 16:21 by timmy40 Presumably the management are impatient with the share price. They have repositioned the company, increased the supply chain and revenue, but the share price has hardly moved for years now. They could always move the listing to the US, but a sale would seem like a reasonable option, although, we're not going to vote in favour without a decent premium imo |
Posted at 11/8/2022 11:11 by livewireplus :-)) unfortunately no refunds ... but had some good times ... have ended-up married - but as wife earns more than me then can't complain .... pass the Tissue from the left-hand side. An interesting week so far for the TRX share price .... |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
